Biomarkers for pre-selection of patients for anti-IGF1R therapy
US7811562B2 · kind B2 · utility
1Cited by
19References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 30, 2005 |
| Grant date | Oct 12, 2010 |
| Priority date | — |
| Expiry date | Nov 30, 2025 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/56
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides methods for identifying patients whose cancers are likely to be responsive to IGF1R inhibitory anti-cancer therapy along with methods for treating such patients. Patients identified by a method of the present invention can be treated with any of several known IGF1R inhibitory agents including antibodies, small molecule inhibitors and anti-sense nucleic acids.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.